ADC_Header_2

LAVERDIA-CA1 (verdinexor): A new oral treatment option for canine lymphoma

1 hr CE Credit
Exclusively for Animal Dermatology Clinic

Watch On Demand

In this CE session, we'll review the latest best practices for managing canine lymphoma. We'll also talk about how the first FDA conditionally approved oral tablet to treat dogs with lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and clients more options and increasing access to cancer care.

LAVERDIA-CA1 (verdinexor) is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.

Hosted by

Dr. David Bruyette

DVM, DACVIM (SAIM)

Chief Medical Officer

Anivive

David Bruyette
You'll learn:
  • Evolving protocols for treating canine lymphoma
  • How SINE class drugs, like LAVERDIA-CA1, work
  • Clinical applications, including cutaneous lymphoma
  • Guidelines to optimize patient outcomes

I acknowledge that by registering for this webinar Anivive may email me about this event and other events and news.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions that recognize RACE approval. Anivive RACE Provider #50-30163